Cas no 3385-03-3 (Flunisolide)

Flunisolide is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, primarily used in the treatment of allergic rhinitis and asthma. Its mechanism of action involves inhibiting the release of inflammatory mediators, reducing mucosal edema, and suppressing eosinophil activity. Flunisolide is administered via nasal spray or inhalation, ensuring localized delivery with minimal systemic absorption, thereby reducing the risk of adverse effects associated with systemic corticosteroids. The compound exhibits high glucocorticoid receptor affinity, contributing to its efficacy at low doses. Its favorable pharmacokinetic profile, including rapid metabolism and clearance, further enhances its therapeutic utility. Flunisolide is valued for its targeted action and safety in long-term management of chronic inflammatory respiratory conditions.

Flunisolide structure

Product Name:Flunisolide

CAS No:3385-03-3

MF:C₂₄H₃₁FO₆

MW:434.49775147438

CID:44090

PubChem ID:24894879

Update Time:2025-05-20

Flunisolide Chemical and Physical Properties

Names and Identifiers

- Flunisolide
- (6a,11b,16a)-6-Fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione
- Syntaris
- UNII-78M02AA8KF
- HMS1570A07
- Prestwick2_000643
- BCP9000696
- EN300-7480609
- PREGNA-1,4-DIENE-3,20-DIONE, 6-FLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))- (6.ALPHA.,11.BETA.,16.ALPHA.)-
- HMS3714A07
- Flunie
- Syntaris Hayfever
- BDBM50248007
- Prestwick0_000643
- CCG-220643
- Flunisolide [INN]
- 3385-03-3
- Flunisolide Hemihydrate
- SMR001233272
- RS-3999
- CS-4713
- Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-
- FLUNISOLIDE [WHO-DD]
- Aerospan HFA
- BPBio1_000711
- Prestwick1_000643
- BSPBio_000645
- HMS2236A06
- Flunisolidum [INN-Latin]
- HMS2097A07
- CHEMBL1512
- 6.ALPHA.-FLUORO-11.BETA.,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE CYCLIC 16,17-ACETAL WITH ACETONE
- DB00180
- Flunisolide anhydrous
- C07005
- Flunisolide [anhydrous]
- Lunis
- Nasalide
- HY-B1121
- NC00716
- SCHEMBL4351
- Aerobid
- Pregna-1,4-diene-3,20-dione, 6-alpha-fluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone
- 6-Fluoro-11,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione 16,17-acetonide
- Q3746835
- Aerospan
- Bronalide
- NCGC00016983-01
- FLUNISOLIDE [MI]
- Prestwick3_000643
- GTPL7076
- Synaclyn
- Rhinalar
- Flunisolida
- Pregna-1,4-diene-3,20-dione,6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6a,11b,16a)-
- DTXCID9025534
- NCGC00179492-03
- 6alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone
- NSC-757871
- lunisolide anhydrous
- EINECS 222-193-2
- F0437
- Flunisolide HFA
- BRD-K49577446-001-03-1
- Tox21_110725_1
- NCGC00179492-01
- (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one
- Tox21_110725
- MFCD00133324
- CHEBI:5106
- D78324
- AKOS025402038
- Nisolid
- AC-3514
- Flunisolida [INN-Spanish]
- 78M02AA8KF
- CAS-3385-03-3
- Prestwick_223
- Aerobid M
- DTXSID1045534
- SPBio_002566
- (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
- MLS002153928
- 6alpha-fluoro-11beta,21-dihydroxy-16alpha,17alpha-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione
- HMS3259L10
- NS00067047
- RS 3999
- Nasarel
- Flunisolidum
- Soluzione
- 6-Fluoro-11,21-dihydroxy-16,17-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione
- XSFJVAJPIHIPKU-XWCQMRHXSA-N
- 77326-96-6
- MDL： MFCD00133324
- Inchi： 1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1
- InChI Key： XSFJVAJPIHIPKU-XWCQMRHXSA-N
- SMILES： F[C@@H]1C2=CC(C=C[C@]2(C)[C@H]2[C@H](C[C@]3(C)[C@@]4(C(CO)=O)[C@@H](C[C@H]3[C@@H]2C1)OC(C)(C)O4)O)=O

Computed Properties

Exact Mass: 434.21000
Monoisotopic Mass: 434.21
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 6
Heavy Atom Count: 31
Rotatable Bond Count: 2
Complexity: 910
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 9
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Surface Charge: 0
Tautomer Count: 3
XLogP3: 2.5
Topological Polar Surface Area: 93.1

Experimental Properties

Color/Form: Not determined
Density: 1.1517 (estimate)
Melting Point: 237-240°C (dec.)
Boiling Point: 581.8oC at 760mmHg
Flash Point: 305.7oC
Solubility: Chloroform (Sparingly), Methanol (Slightly)
PSA: 93.06000
LogP: 2.27470
Merck: 4145
Solubility: Not determined
Vapor Pressure: 0.0±3.7 mmHg at 25°C

Flunisolide Security Information

Symbol:
Signal Word：Danger
Hazard Statement： H300
Warning Statement： P264-P301 + P310
WGK Germany：3
Hazard Category Code： 28
Safety Instruction： 28-36/37-45
RTECS：TU3900000
Hazardous Material Identification：
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Flunisolide Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.	R032453-100mg	Flunisolide	3385-03-3	97%	100mg	￥2765	2024-05-24
ChemScence	CS-4713-100mg	Flunisolide	3385-03-3	99.95%	100mg	$320.0	2022-04-27
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.	F863904-100mg	Flunisolide	3385-03-3	≥97%	100mg	￥2,400.00	2022-01-11
TRC	F500485-1mg	Flunisolide	3385-03-3		1mg	$ 127.00	2023-09-07
TRC	F500485-2.5mg	Flunisolide	3385-03-3		2.5mg	$ 251.00	2023-09-07
TRC	F500485-10mg	Flunisolide	3385-03-3		10mg	$ 925.00	2023-09-07
TRC	F500485-25mg	Flunisolide	3385-03-3		25mg	$1979.00	2023-05-18
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.	F863904-50mg	Flunisolide	3385-03-3	≥97%	50mg	￥1,388.00	2022-01-11
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.	F68960-100mg	Flunisolide	3385-03-3	97%	100mg	￥2878.0	2023-09-07
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.	ajce47736-100mg	Flunisolide	3385-03-3	98%	100mg	￥756.00	2023-09-08

Flunisolide Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:3385-03-3)Flunisolide

Order Number:LE12287

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:06

Price ($):discuss personally

Email:[email protected]

Flunisolide Related Literature

1. Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study

Ayman Abo Elmaaty,Radwan Alnajjar,Mohammed I. A. Hamed,Muhammad Khattab,Mohamed M. Khalifa,Ahmed A. Al-Karmalawy RSC Adv. 2021 11 10027
2. Virtual hydrate screening and coformer selection for improved relative humidity stability

Yuriy A. Abramov CrystEngComm 2015 17 5216
3. A comprehensive and high-throughput screening method for multiple prohibited substances by UPLC-QE Plus-HRMS and HPLC-QQQ-MS in human urine for doping control

Yunxi Liu,Tianyu Dong,Kuan Yan,Zhanliang Wang,Genye He,Yufeng Zhang,Congcong Ma,Lu Liu,Wei Chang,Lisi Zhang Anal. Methods 2023 15 3206

Related Categories

Other Chemical Reagents

Additional information on Flunisolide

Flunisolide (CAS No. 3385-03-3): A Comprehensive Guide to Its Uses, Benefits, and Modern Applications

Flunisolide (CAS No. 3385-03-3) is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. Widely recognized for its therapeutic efficacy in respiratory conditions, this compound has garnered significant attention in both clinical and research settings. As a glucocorticoid receptor agonist, Flunisolide is primarily administered via inhalation to treat allergic rhinitis and asthma, making it a cornerstone in managing chronic inflammatory airway diseases.

In recent years, the demand for Flunisolide-based treatments has surged, driven by rising global prevalence of respiratory disorders. Patients and healthcare providers frequently search for terms like "Flunisolide side effects", "Flunisolide vs. other corticosteroids", and "long-term use of Flunisolide", reflecting growing concerns about efficacy and safety. Studies highlight its localized action, which minimizes systemic side effects compared to oral corticosteroids—a key advantage for chronic users.

The pharmacological profile of Flunisolide (CAS No. 3385-03-3) is characterized by its high receptor binding affinity and lipophilicity, enabling rapid tissue penetration and prolonged activity. This aligns with current trends favoring targeted drug delivery systems, a hot topic in pharmaceutical innovation. Researchers are also exploring its potential in combination therapies, particularly with bronchodilators, to enhance outcomes in severe asthma cases.

Environmental and patient-specific factors, such as pollution and genetic predispositions, have intensified interest in personalized Flunisolide dosing. Emerging data suggest that biomarker-guided treatment could optimize its use, addressing queries like "how to adjust Flunisolide for seasonal allergies" or "Flunisolide for pediatric asthma". These discussions underscore the need for tailored approaches in respiratory care.

From a formulation standpoint, Flunisolide is available as nasal sprays and metered-dose inhalers, with advancements in propellant-free devices gaining traction. This evolution responds to environmental concerns over traditional inhaler propellants, echoing broader sustainability trends in healthcare. Patients increasingly seek eco-friendly alternatives, tying Flunisolide to the larger dialogue on green pharmacology.

Ongoing clinical trials are investigating Flunisolide's role in post-COVID respiratory complications, a timely application given the pandemic's aftermath. Searches for "Flunisolide and long COVID" have spiked, reflecting public interest in repurposing existing drugs for novel indications. Such explorations highlight the compound's versatility beyond classical uses.

Quality control remains critical for Flunisolide (CAS No. 3385-03-3) manufacturing, with stringent pharmacopoeial standards ensuring batch consistency. Analytical techniques like HPLC and mass spectrometry are employed to verify purity, addressing professional queries about "Flunisolide stability testing" and "impurity profiling". These protocols align with regulatory emphasis on drug safety and efficacy.

In summary, Flunisolide exemplifies how legacy pharmaceuticals adapt to contemporary needs. Its intersection with precision medicine, sustainable delivery systems, and emerging therapeutic areas positions it as both a mainstay and a frontier in respiratory therapy. For those navigating allergic or asthmatic conditions, understanding Flunisolide's nuanced benefits is more relevant than ever.

3385-03-3 (Flunisolide) Related Products

Recommended suppliers